prikaz prve stranice dokumenta NOVI TERAPIJSKI PRISTUP KRONIČNOJ OPSTRUKTIVNOJ PLUĆNOJ BOLESTI
  Download
PDF 680.96 KB
master's thesis
NOVI TERAPIJSKI PRISTUP KRONIČNOJ OPSTRUKTIVNOJ PLUĆNOJ BOLESTI
Rijeka: University of Rijeka, Faculty of Medicine, 2018. urn:nbn:hr:184:372361
Dubovečak, Marin
University of Rijeka
Faculty of Medicine
Department of Internal Medicine

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Dubovečak, M. (2018). NOVI TERAPIJSKI PRISTUP KRONIČNOJ OPSTRUKTIVNOJ PLUĆNOJ BOLESTI (Master's thesis). Rijeka: University of Rijeka, Faculty of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:184:372361

Dubovečak, Marin. "NOVI TERAPIJSKI PRISTUP KRONIČNOJ OPSTRUKTIVNOJ PLUĆNOJ BOLESTI." Master's thesis, University of Rijeka, Faculty of Medicine, 2018. https://urn.nsk.hr/urn:nbn:hr:184:372361

Dubovečak, Marin. "NOVI TERAPIJSKI PRISTUP KRONIČNOJ OPSTRUKTIVNOJ PLUĆNOJ BOLESTI." Master's thesis, University of Rijeka, Faculty of Medicine, 2018. https://urn.nsk.hr/urn:nbn:hr:184:372361

Dubovečak, M. (2018). 'NOVI TERAPIJSKI PRISTUP KRONIČNOJ OPSTRUKTIVNOJ PLUĆNOJ BOLESTI', Master's thesis, University of Rijeka, Faculty of Medicine, accessed 23 May 2024, https://urn.nsk.hr/urn:nbn:hr:184:372361

Dubovečak M. NOVI TERAPIJSKI PRISTUP KRONIČNOJ OPSTRUKTIVNOJ PLUĆNOJ BOLESTI [Master's thesis]. Rijeka: University of Rijeka, Faculty of Medicine; 2018 [cited 2024 May 23] Available at: https://urn.nsk.hr/urn:nbn:hr:184:372361

M. Dubovečak, "NOVI TERAPIJSKI PRISTUP KRONIČNOJ OPSTRUKTIVNOJ PLUĆNOJ BOLESTI", Master's thesis, University of Rijeka, Faculty of Medicine, Rijeka, 2018. Available at: https://urn.nsk.hr/urn:nbn:hr:184:372361

Metadata
TitleNOVI TERAPIJSKI PRISTUP KRONIČNOJ OPSTRUKTIVNOJ PLUĆNOJ BOLESTI
Title (english)NEW THERAPEUTIC APPROACH TO CHRONIC OPSTRUCTIVE PULMONARY DISEASE
AuthorMarin Dubovečak
MentorLjiljana Bulat-Kardum (mentor)
Committee memberDubravka Matanić Lender (predsjednik povjerenstva)
Committee memberSrđan Banac (član povjerenstva)
Committee memberIgor Barković (član povjerenstva)
GranterUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Rijeka
Defense date and country2018-07-13, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract
Kronična opstruktivna plućna bolest (KOPB) progresivna je bolest karakterizirana ireverzibilnom opstrukcijom dišnih puteva. Najvažniji uzrok nastanka KOPB-a je dugotrajno izlaganje duhanskome dimu. Najvažniji postupak u dijagnostici opstrukcije dišnih puteva je spirometrija. S novim GOLD smjernicama iz 2017., spirometrijski pokazatelji opstrukcije, FEV1 i omjer FEV1/FVC isključeni su iz terapijskog algoritma bolesti te se terapijski algoritam temelji na simptomima i egzacerbacijama bolesti. Temelj liječenja KOPB-a predstavljaju bronhodilatacijski lijekovi u monoterapiji i dvojnoj bronhodilatacijskoj terapiji. Dokazana je korist dualne bronhodilatacijske terapije u odnosu na monoterapiju u liječenju stabilne bolesti, dok su ICS indicirani za manju skupinu bolesnika sa brojnim simptomima i učestalim egzacerbacijama, sa eozinofilijom sputuma i vrijednostima FEV1 ispod 50%, te bolesnicima s ACO, jer u većoj skupini bolesnika korist ICS-a ne nadmašuje potencijalne nuspojave.
Abstract (english)
Chronic obstructive pulmonary disease (COPD) is characterized by irreversible obstruction of the respiratory tract. The most important cause of COPD is the long-term exposure to tobacco smoke. The most important procedure in the diagnosis of respiratory obstruction is spirometry. With the new 2017 GOLD guidelines, spirometric obstruction indicators, FEV1 and FEV1/FVC are excluded from the therapeutic algorithm of the disease, and the therapeutic algorithm is based on symptoms and exacerbations of the disease. The basis of COPD treatment is bronchodilatory medications in monotherapy and dual bronchodilation therapy. There was evidence of dual bronchodilation therapy compared to monotherapy in the treatment of stable disease, while ICS was indicated for a smaller group of patients with numerous symptoms and frequent exacerbations, spontaneous eosinophilia and FEV1 values below 50%, and patients with ACO, because in a larger group of patients the benefit of ICS does not outweigh the potential side effects.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:184:372361
Study programmeTitle: Medicine
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2018-12-06 15:51:40